Sustained pain‐free during the 24 h post dose for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
Sustained headache relief during the 24 h post dose for moderate or severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
High
At least 1 AE during treatment for moderate to severe baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
At least 1 AE during treatment for mild baseline pain · adults with migraine headache ‐ moderate or severe and mild baseline pain
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious AE (all levels of baseline pain) · adults with migraine headache ‐ moderate or severe and mild baseline pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy
1 finding from 1 review
Intervention not reported
Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy
1 finding from 1 review
Intervention not reported
Pain intensity VAS score1 mg morphine vs 4 mg/5 mg morphine 0‐10 cm VAS score. Scale from: 0 to 10. · patients undergoing knee arthroscopy
1 finding from 1 review
Intervention not reported
Analgesia duration 1 mg morphine vs 4 mg/5 mg morphinetime duration from the end of surgery to the first time of analgesic consumption · patients undergoing knee arthroscopy
1 finding from 1 review
Intervention not reported
Adverse events 1 mg morphine vs 4 mg/5 mg morphinePercentage of participants with any adverse event · patients undergoing knee arthroscopy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes at 24 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to higher participants free from relapse compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from disability worsening · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from disability worsening compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Annualised relapse rate · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg probably leads to lower annualised relapse rate compared with placebo (moderate certainty).
1 finding from 1 review
Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).
1 finding from 1 review
Outcomes at 12 months · patients with relapsing‐remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found